Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

This study has been completed.

Sponsor:

Information provided by:

Eli Lilly and Company

ClinicalTrials.gov Identifier:

NCT00051909

First received: January 17, 2003

Last updated: July 18, 2006

Last verified: July 2006

History of Changes

Tracking Information
First Received Date ^ICMJE	January 17, 2003
Last Updated Date	July 18, 2006
Start Date ^ICMJE	November 2002
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00051909 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Official Title ^ICMJE	Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Brief Summary	Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 2
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Condition ^ICMJE	Alzheimer's Disease
Intervention ^ICMJE	Drug: LY451395
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	200
Completion Date	June 2003
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: Must have a clinical diagnosis of Alzheimer's Disease Must be at least 50 years of age Must fluently read and speak English Must have a reliable caregiver Exclusion Criteria: Has serious health problems other than Alzheimer's Disease Cannot swallow whole pills Has had a menstrual period in the last two years Takes insulin for diabetes Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Gender	Both
Ages	50 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00051909
Other Study ID Numbers ^ICMJE	6764, H6N-MC-LEAM
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Eli Lilly and Company
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Eli Lilly and Company
Verification Date	July 2006
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top